U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test
Epigenomics AG announced that Quest Diagnostics Incorporated successfully completed the clinical validation of its Septin9-based laboratory-developed test for aiding the detection of colorectal cancer. Under terms of a license agreement between the companies for Epigenomics' proprietary DNA methylation biomarker Septin9, Epigenomics will receive a milestone payment from Quest Diagnostics upon reaching this milestone. The amount of the payment was not disclosed.
"Validation of our Septin9 laboratory-developed test is an important step forward in providing a test that physicians can use to help them identify patients with colorectal cancer," said Jay G. Wohlgemuth, M.D., Vice President of Science and Innovation, Quest Diagnostics. "We intend to release the test in the U.S. later this year."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Merck Opens New Life Science Center for Scientific Collaboration
Computer superpower strengthens attempts to combat common diseases
